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Background: Early and late microvascular obstruction (MVO) assessed by cardiovascular magnetic resonance (CMR)
are prognostic markers for short-term clinical endpoints after acute ST-elevation myocardial infarction (STEMI).
However, there is a lack of studies with long-term follow-up periods (>24 months).
Methods: STEMI patients reperfused by primary angioplasty (n = 129) underwent MRI at a median of 2 days after
the index event. Early MVO was determined on dynamic Gd first-pass images directly after the administration of
0.1 mmol/kg bodyweight Gd-based contrast agent. Furthermore, ejection fraction (EF, %), left ventricular myocardial
mass (LVMM) and total infarct size (% of LVMM) were determined with CMR. Clinical follow-up was conducted
after a median of 52 months. The primary endpoint was defined as a composite of death, myocardial re-infarction,
stroke, repeat revascularization, recurrence of ischemic symptoms, atrial fibrillation, congestive heart failure
and hospitalization.
Results: Follow-up was completed by 107 patients. 63 pre-defined events occurred during follow-up. Initially,
74 patients showed early MVO. Patients with early MVO had larger infarcts (mean: 24.9 g vs. 15.5 g, p = 0.002) and a
lower EF (mean: 39% vs. 46%, p = 0.006). The primary endpoint occurred in 66.2% of patients with MVO and in
42.4% of patients without MVO (p< 0.05). The presence of early MVO was associated with a reduced event-free
survival (log-rank p< 0.05). Early MVO was identified as the strongest independent predictor for the occurrence of
the primary endpoint in the multivariable Cox regression analysis adjusting for age, ejection fraction and infarct
size (hazard ratio: 2.79, 95%-CI 1.25-6.25, p = 0.012).
Conclusion: Early MVO, as assessed by first-pass CMR, is an independent long-term prognosticator for morbidity
after AMI.
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Microvascular obstruction (MVO) after primary percu-
taneous coronary intervention (pPCI) for acute ST-
elevation myocardial infarction (STEMI) is a no reflow
phenomenon in coronary vessels smaller than 200 μm
despite adequate epicardial reperfusion [1]. Microvascular
no-reflow can be caused by an interplay of multiple* Correspondence: Bernhard.Metzler@uki.at
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reproduction in any medium, provided the orfactors, including embolization of thrombus and plaque,
endothelial dysfunction, inflammation, myocardial edema
and microvascular dysfunction after treatment of STEMI
[2-5].
Classical measures of MVO are the thromobolysis in
myocardial infarction (TIMI) myocardial perfusion grade
[6] and myocardial blush grade [7] after successful epi-
cardial perfusion as assessed by TIMI flow grade [8].
Myocardial perfusion grade and myocardial blush grade
are associated with mortality after thrombolytic [6] and
percutaneous [7] restoration of blood flow after myocar-
dial infarction, independent of TIMI flow.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cepts of first-pass perfusion and late-Gd-enhancement
(LGE) imaging is a unique tool for investigating MVO
[9-12]. Early MVO is defined as a prolonged (~60 sec)
perfusion deficit in first-pass images [13]. Late MVO is
usually assessed as an hypointense infarct core on LGE
images acquired 10 min after contrast application [14].
Especially early MVO has been shown to correlate well
with angiographic myocardial blush grade [15]. MVO
can be studied by CMR at least up to 1 week after pPCI
for STEMI [16].
The morphological type of coronary lesion, a large ves-
sel diameter and a high thrombus load have an impact
on the occurrence of slow- or no-reflow phenomenon
after primary angioplasty [17]. Furthermore, MVO is
predicted by the extent of the ischemic region and is
associated with decreased baseline ejection fraction and
wall motion scores[18]. We have previously shown the
relation of cardiac troponin and C-reactive protein to
MVO after successful pPCI for STEMI [14]. Both early
[19] and late [11,20] MVO have been shown to be sig-
nificant and independent prognostic factors affecting
clinical outcomes. So far, vasodilators [21,22], antiplate-
let drugs [23] and thrombus aspiration [24] have been
used with varying results [25]. The use of CMR in the
detection of MVO offers new possibilities in the search
for drugs to prevent MVO. Large multicenter trials now
use CMR as the primary endpoint [26].
Despite the increasing awareness of the clinical
importance of MVO, there is a lack of long-term follow-
up (>24 months) studies. Therefore, the aim of this
study was to (a) assess clinical variables associated with
early MVO and (b) evaluate the prognostic value of early
MVO during a long-term follow-up (5 years).
Methods
Patient population
Patients reperfused by pPCI for STEMI at the University
Hospital Innsbruck between 01/2005 and 12/2007 were
asked to participate in the study. One-hundred and
twenty-nine patients fulfilled inclusion criteria and gave
their informed consent. The study was approved by the
local ethics committee.
Inclusion criteria were (a) diagnosis of ST-elevation
myocardial infarction (STEMI) according to the rede-
fined ESC/ACC committee criteria [27] as first cardiac
event (b) the exact determination of time from onset of
symptoms until revascularization of infarct-related artery
(pain–to-balloon-time), (c) Killip class <2 and no pre-
existing condition of heart failure. Furthermore, only
patients with (d) no contraindications to CMR were eli-
gible for this study.
Clinical follow-up was completed in 12/2010. The end-
points were defined by a consensus of the primarilyinvolved investigators who were blinded to the CMR
results. The primary endpoint was defined as a composite
of death, myocardial re-infarction, stroke, repeat revascu-
larization, recurrence of ischemic symptoms, atrial fibril-
lation, congestive heart failure and hospitalization of any
cause. Secondary endpoints were defined as the individual
endpoints of the composite primary endpoint.
Ischemic symptoms were defined as the presence of
typical anginal pain. Congestive heart failure was defined
as episodes of cardiac decompensation, including ede-
mas or worsening dyspnea of at least NYHA class III-IV
requiring medical attention. If more than one end-point
occurred in one patient the earliest and/or most severe
end-point was chosen.
Biochemical measurements
CK activity was determined by an enzymatic assay
(Roche Diagnostics, Mannheim, Germany) and cTnT
concentrations were measured by 4th generation cTnT
enzyme immunoassays (Roche Diagnostics, Mannheim,
Germany) [28].
Blood samples for CK and cTnT measurements were
collected routinely according to a standard protocol at
least 3 times during the first 24 hours after admission
and then daily. Maximum CK and cTnT levels as well as
estimated cumulative CK and cTnT release were deter-
mined. Maximum cTnT and CK values served as an esti-
mate of infarct size [29,30].
Cardiovascular magnetic resonance
CMR was performed within at most 8 days after STEMI
during hospitalization. All studies were performed on a
1.5 Tesla (T) MR scanner (Magnetom Avanto, Siemens,
Erlangen, Germany). The CMR protocol was described
in detail previously [12] (Figure 1a).
End-diastolic volume (EDV) and end-systolic volume
(ESV) as well as ejection fraction (EF) and myocardial
mass (MM) were obtained from short axis cine-MR
images, acquired using breath-hold, with retrospective
ECG-triggered true-FISP. Evaluation was performed on
standard software (ARGUS, Siemens) by an experienced
reader (G.K.) blinded to the clinical data.
First-pass perfusion images were obtained in three
short-axis sections centered on the mid-papillary muscle
using an electrocardiograph-triggered T1-weighted
inversion-recovery true-FISP sequence. A bolus injection
of 0.1 mmol/kg body mass gadolinium contrast bolus
(Spectris, Medrad, Pittsburgh, PA) was administered by
using an infusion pump (Spectris, Medrad, Pittsburgh,
PA) at 5 ml/sec [31]. Sixty dynamic images were
acquired simultaneously at each of the three sections
during the first pass of the contrast agent within the
myocardium. Registration of microvascular perfusion
defects on first-pass perfusion images was performed
Figure 1 Consecutive slices acquired during first gd-pass (a). The flow-chart below (b) shows the timeline of one CMR. RV: right ventricle,
LV: left ventricle, SA: short axis, 4CH: four chamber, Gd: gadolinium, BW: bodyweight, PSIR-FISP: phase-sensitive inversion-recovery fast-imaging-in-steady-
state-precession.
Klug et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:46 Page 3 of 10
http://www.jcmr-online.com/content/14/1/46two times by an experienced observer (A.M.) blinded to
the clinical measurements. Early MVO was considered
qualitatively to be present if a region of hypoperfusion
persisted on at least 5 consecutive temporal images after
contrast bolus arrival in the left ventricle and was
located in the subendocardial layer of the infarct core in
at least 1 of the short-axis slices. To verify that a true
perfusion deficit persisted after passage of the contrast
agent, all acquired phases were evaluated [14] (see
Figure 1b).Ten min after a second intravenous gadolinium bolus
injection of 0.1 mmol/kg body mass, LGE-CMR images
were acquired by using an ECG-triggered phase-
sensitive inversion-recovery (PSIR) single shot true-FISP
sequence with consecutive short-axis slices as described
in detail previously [12]. The area of LGE was evaluated
quantitatively for each slice using a commercially avail-
able software tool (J-Vision vs. 3.3.16, TIANI Medgraph,
Brunn am Gebirge, Austria); enhancement was defined
using a threshold of +5 SD above the signal intensity of
Klug et al. Journal of Cardiovascular Magnetic Resonance 2012, 14:46 Page 4 of 10
http://www.jcmr-online.com/content/14/1/46normal myocardium in the opposite myocardial segment
[32-34]. Furthermore, on LGE images a persisting area
of low signal, surrounded by enhanced myocardial tissue
was considered as late-MVO and quantified by manual
contouring of the unenhanced myocardium. Late-MVO
mass as well as the percentage of late-MVO myocar-
dium were calculated.
Statistical analysis
For statistical analysis, the statistical software package
SPSS 15.0 (SPSS, Chicago, IL) was used. All results for
continuous variables are expressed as mean ± standard
deviation (SD) or, if stated otherwise, as medians with
corresponding interquartile range (IQR). Kolmogorov-
Smirnov test was used to test for normal distribution
(ND). χ2-test was used to compare categorical variables
between groups. ANOVA with Bonferroni post-hoc test-
ing (if ND) and Mann–Whitney U or Kruskal-Wallis
test (M-W or K-W, if not ND) were used to determine
differences in continuous variables between groups.
Pearson test was used for calculation of linear correla-
tions for selected variables if they were ND. Otherwise,
Spearman rank correlations were calculated. A p value
p< 0.05 was considered to indicate statistical signifi-
cance. Kaplan-Meier survival curves were determined
and log-rank comparison was used between groups. Uni-
and multivariate Cox-regression analysis was used to
estimate hazard ratios (HR).
Results
Patients and follow-up
Out of 129 patients, 5 patients (3.9%) did not complete
the CMR due to claustrophobia, 124 patients underwent
CMR scan within a median of 2 days (IQR: 2–4). Three
(2.4%) scans were not diagnostic because of image qual-
ity. The remaining 121 patients were contacted after a
median of 1613 days (IQR: 1374–1832 days). One-
hundred and seven patients (88.4%) completed the
follow-up. 11 (9.1%) patients were lost to follow-up,
3 (2.5%) patients could not be contacted for language
reasons (see study flow-chart, Figure 2).
Study population baseline characteristics
The mean age of the study population was
57.0 ± 12.0 years (range 31 to 85 years); 99 patients
(83.9%) were male, 19 (16.1%) were female. All patients
underwent successful PCI of the culprit lesion with a
median delay of 210 minutes (IQR: 120–330). 12 of
them obtained additional prehospital fibrinolysis. For
detailed patients characteristics, see Table 1.
On initial CMR scans, 74 patients showed early MVO
(eMVO+, 69.2%). eMVO+patients had a higher preva-
lence of hypertension (65.8% vs. 45.5%, χ2: 3.88, p< 0.05)
but did not differ from patients without early MVO(eMVO-) with regard to age, sex, body mass index
(BMI) or the prevalence of the remaining cardiovascular
risk factors (all p> 0.05). Furthermore, pain-to-balloon
time, administration of prehospital lysis and mean pre-
or post-interventional TIMI flow did not differ signifi-
cantly between the groups (all p> 0.05).
With regard to measures of infarct size, eMVO+
patients had larger infarcts as determined by LE-CMR
(24.9 ± 15.2 g vs. 15.5 ± 16.1 g, ANOVA p< 0.01),
more transmural infarctions (92.9% vs 66.7%, χ2: 15.27,
p< 0.002) and higher maximum biomarker levels
(CKmax: 2844.8 ± 1992.7 vs. eMVO- 1492.4 ± 1802.5 U/l,
cTnTmax: 8.02 ± 5.19 vs. eMVO- 4.30± 4.71 μg/ml,
ANOVA p< 0.002) (see Figure 3). Left ventricular ejec-
tion fraction was impaired in eMVO+patients
(39.2 ± 11.4% vs eMVO- 46.1 ± 8.9%, ANOVA p< 0.01).
We observed no significant difference in the occurrence
of ST-segment resolution >50% (p> 0.05).Primary endpoint
Sixty-three predefined primary endpoints occurred dur-
ing follow-up. Primary endpoint occurred in 66.2% of
patients with MVO and in 42.4% of patients without
MVO (χ2: 5.34, p< 0.05). Kaplan-Meier curves demon-
strate a significantly reduced event-free survival times
for eMVO+patients (median: 930, IQR: 290–1428 days)
compared to eMVO- patients (median: 1141, IQR: 343–
1427 days) (log-rank p< 0.05, Figure 4).
Presence of early MVO showed a strong univariate
association with the occurrence of the primary endpoint
(HR: 1.88, 95%-CI: 1.04.-3.40, p = 0.029). Early MVO was
associated with the occurrence of the primary endpoint
when adjusting for age, ejection fraction and infarct
size (HR: 2.06, 95%-CI 1.04-4.09, p = 0.039). Compared
to age above median (=57 years), EF below median
(=40.6%) and infarct size above median (=19.77 g)
eMVO was the strongest independent predictor for the
occurrence of the primary endpoint (HR: 2.20, 95%-CI
1.11-4.36, p = 0.024, see Table 2).Secondary endpoints
149 individual secondary endpoints occurred in patients
with early MVO and 36 in patients without MVO.
Table 3 shows the differences between patients with and
without MVO regarding the occurrence of secondary
endpoints. Patients with MVO suffered more frequently
from recurrence of ischemic symptoms (24.7% vs 6.1%,
χ2: 5.13, p = 0.023), congestive heart failure (12.3% vs
0.0%, χ2: 4.45, p0.035) and hospitalizations (60.3% vs.
39.4%, χ2: 3.99, p = 0.046). The incidence of death, CV-
death and myocardial re-infarction did not reach statis-
tical significance.
Figure 2 Study flow-chart. STEMI: ST-segment elevation myocardial infarction, PCI: percutaneous coronary interventions, CMR: cardiac
magnetic resonance.
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The primary results of this study are: (a) patients with
early MVO had a higher prevalence of preexisting hyper-
tension, but apart from that, showed similar risk profiles
with regard to age, BMI, lipid status, smoking habits,
diabetes and family history. (b) In line with most other
MVO studies, a strong correlation between infarct size
and early MVO was observed. (c) Early MVO is an inde-
pendent long-term prognosticator of adverse clinical out-
comes, especially recurrent ischemic symptoms, heart
failure and repeat hospitalization, in a very long follow-up.
Patient characteristics and microvascular obstruction
MVO is an increasingly recognised phenomenon after
pPCI for STEMI. Prevalence between 25%[19] and 79%
[20] are described in recent literature. In our study, 69%
of the patients showed eMVO.
Recently, two studies investigated predictors of late
MVO defined by CMR, ECG and angiographic analysis
[18,35]. Their results suggest an association of MVO
with age, diabetes [35] and hyperglycemia[18,36]. Due to
the sample size of our study we cannot preclude an
impact of diabetes or age on the presence of eMVO only
by the lack of statistical significance. Our data, how-
ever, is in line with a recent larger studie [20]. It is likely
that the lower age (56.8 yrs vs. 60 yrs [35], 63 yrs [18]
and 66 yrs [20]) and the lower prevalence of diabetes
(8.4% vs. 17% [35], 16% [18] and 27% [20]) can be the
explanation for the lack of statistical significance in our
study group.In our study, the prevalence of hypertension was sig-
nificantly higher in patients with eMVO (65.8% vs.
eMVO- 45.5%) which has, to the best of our knowledge,
not been described previously. Data on the effects of
hypertension on the cardiac microvasculature suggest
impaired endothelial function in hypertensive subjects
[37], which in turn might exaggerate microvascular
dysfunction in patients after STEMI[1]. Interestingly,
Husser et al. observed an inverse association of systolic
blood pressure with the presence of MVO, which unfor-
tunately we did not determine. The results of Husser
et al. are explained by the authors as a result of a signifi-
cant higher Killip class in patients with MVO and the
resulting cardiogenic shock [35].
There was a trend towards a lower number of active
smokers among eMVO+patients (69.7% vs. eMVO-
50.7%, p = 0.052) which was also not observed previ-
ously. In analogy with the explanation of Husser et al.
that younger patients may lack ischemic preconditioning
and coronary collaterals[35], we believe that these
mechanisms might explain our results despite the lack
of statistical significance.
The presence [20] and extent [13,38] of MVO corre-
lates with measures of infarct size as well as with
impaired left ventricular function [20,35]. The ratio of
MVO to infarct size not only correlates with biomarker
levels [14], but is even of superior prognostic value com-
pared to the extent of MVO alone [38]. Our study is in
line with these prior results although the extent of early
MVO was not evaluated. Prior results of our study
Table 1 Patient characteristics
Clinical Charcteristics All (n = 107) eMVO+ (n= 74) eMVO - (n = 33) p-value
Female, n(%) 20 (18.5) 13 (17.6) 7 (21.2) .421
Age, years 56.8 ± 12.0 57.8 ± 12.2 54.6 ± 11.3 .217
BMI, kg/m² 25.5 ± 4.0 25.8 ± 2.7 24.9 ± 5.8 .250
Hypertension, n (%) 64 (59.8) 48 (65.8) 15 (45.5) .040*
Hypercholesterinemia, n(%) 87 (81.3) 61 (83.6) 26 (78.8) .367
Smoking, n(%) 60 (56.1) 37 (50.7) 23 (69.7) .052
Diabetes mellitus, n(%) 9 (8.4) 7 (9.6) 2 (6.1) .427
Family history for CVD, n(%) 21 (19.6) 14 (19.2) 7 (21.2) .500
Pain-to-balloon, min [median] 210 (IQR: 120–330) 210 (IQR: 150–338) 180 (IQR: 60–270) .553
Prehospital lysis, n (%) 12 (11.1) 7 (9.5) 4 (12.1) .456
TIMI pre PCI, n(%) .471
MEAN 0.38 ± 0.8 0.58 ± 0.8 .292
0 61 (72.6) 46 (76.7) 15 (62.5)
1 10 (11.9) 6 (10.0) 4 (16.7)
2 12 (14.3) 7 (11.7) 5 (20.8)
3 1(1.2) 1 (1.7) 0 (0)
TIMI post PCI, n(%)
MEAN 2.95 ± 0.4 2.84 ± 0.5 .260
0 1 (1.2) 1 (0) 0 (0)
1 1 (1.2) 0 (0) 1 (4.0)
2 2 (2.3) 0 (0) 2 (8.0)
3 82 (95.3) 60 (98.4) 22 (88.0)
CKmax, U/l 2460.3 ± 2026.7 2844.8 ± 1992.7 1492.4 ± 1802.5 .002**
cTnTmax, μg/ml 6.96 ± 5.31 8.02 ± 5.19 4.30 ± 4.71 .001**
ST-Resolution, n(%) 52 (80) 33 (78.6) 22 (81.8) .517
Infarct size, g 22.0 ± 16.0 24.9 ± 15.2 15.5 ± 16.1 .006**
Infarct transmurality, n(%) .002**
MEAN 98.2 ± 6.5 85 ± 25.1 <.001**
0-25 3 (3.0) 0 3 (10.0)
25-50 2 (2.0) 0 2 (6.7)
50-75 10 (10.0) 5 (7.1) 5 (16.7)
75-100 85 (85.0) 65 (92.9) 20 (66.7)
Ejection fraction, % 41.1 ± 11.2 39.2 ± 11.4 46.1 ± 8.9 .005**
Early MVO, n(%) 74 (69.2)
Late MVO, n(%) 63 (58.9) 59 (79.7) 4 (12.1) <.001**
NYHA class at follow up, n(%)
MEAN 1.5 ± 0.8 1.2 ± 0.5 .072
I 73 (73.0) 46 (67.6) 26 (83.9)
II 16 (16.0) 12 (17.6) 4 (12.9)
III 9 (9.0) 8 (11.7) 1 (3.2)
IV 2 (2.0) 2 (2.9) 0 (0)
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Table 1 Patient characteristics (Continued)
CCS class at follow-up, n(%)
MEAN 0.43 ± 0.8 0.39 ± 0.7 .808
0 71 (71.0) 48 (70.6) 22 (71.0)
I 19 (19.0) 13 (19.1) 6 (19.4)
II 9 (9.0) 6 (8.8) 3 (9.7)
III 0 (0.0) 0 (0) 0 (0)
IV 1 (1.0) 1 (1.4) 0 (0)
The table is showing the clinical characteristics of the whole study cohort and patients with or without MVO. P-values are given between patients with and
patients without MVO (*p< 0.05, **p< 0.01). Early/late MVO: early microvascular obstruction, BMI: body mass index, CVD: cardiovascular disease, TIMI:
thrombolysis in myocardial infarction, PCI: percutaneous coronary intervention, CKmax: maximum creatine kinase, cTnTmax: maximum cardiac Troponin T, NYHA:
New York Heart Association, CCS: Canadian Cardiovascular Society.
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damage [14] and impaired segmental myocardial func-
tion and functional recovery [39].
Clinical outcomes
These effects of MVO on the cellular and functional
level might explain why the prognostic value of early
[19] and late[38] MVO has frequently been described as
superior to that of infarct size alone. The results of the
present study extend prior studies by an observation
time of 5 years. One limitation of our study, however, is
the relatively small sample size, which necessitates the
use of a combined primary endpoint.
The question whether early or late MVO is of primary
prognostic interest cannot as yet be answered. While
deWaha et al. argue that no hard clinical endpoints
occurred in patients with early but no late MVO [20],
the use of early MVO might have an advantage due to a
higher sensitivity in detecting the same pathophysio-
logical phenomenon [40,41]. Moreover in a subgroup of
40 patients we previously observed that, beside infarct
transmurality, eMVO is the most important imaging
parameter in predicting regional functional recovery
[39]. On the other hand the use of 3 short-axis slices
might underestimate the presence of MVO compared to
the six to eight slices acquired on LGE images.Figure 3 Measures of infarct size in patients with (eMVO+) or withou
whiskers give the 1.5-fold IQR. CKmax: maximum creatine kinase, cTnTmax: mHowever, we believe that the clinical significance of
different results are marginal, especially because the dif-
ferences in total event-rates are small [20]. The results
of our and other previous studies [11,19,20] suggest a
superior prognostic value of MVO compared to that of
infarct size and ejection fraction.
Infarct size and left ventricular EF alone have been
shown to be significant prognostic parameters after
STEMI in large CMR-trials [42]. In our study group,
however, the univariate impact of classical prognostic
markers was not statistically significant. One explanation
might be the small sample size of our study, which only
allows for the most important parameter, namely MVO,
to reach a significant number of clinical endpoints.
In our study, eMVO+patients differed from eMVO-
patients in the occurrence of recurrent ischemic symp-
toms (24.7% vs. 6.1%, p< 0.05), congestive heart failure
(12.3% vs. 0%, p< 0.05) and hospitalisations of any kind
(60.3% vs. 39.4%, p< 0.05). In line with these results, we
observed a trend for a higher NYHA class at follow-up
(eMVO+: 1.5 ± 0.8 vs. eMVO-: 1.2 ± 0.5, M-W p= 0.072)
as well as a trend for a higher number of cardiovascular
hospitalisations (46.6% vs. 28.1%, χ2: 3.13, p = 0.077) and
atrial fibrillation (8.2% vs. 0%, χ2: 2.88, p = 0.09).
The fact that the presence of MVO leads to a higher
rate of recurrent ischemic symptoms during follow-upt (eMVO-) microvascular obstruction. Boxes give the IQR and
aximum cardiac Troponin T.
Table 3 Occurrence of secondary endpoints
Secondary Endpoints,
n (%)
eMVO+ (n= 74) eMVO - (n = 33) p-value
Death 3 (4.1) 1 (3.0) .797
CV-death 2 (2.7) 1 (3.0) .678
Re-infarction 9 (12.3) 2 (6.1) .327
Re-CAG 23 (31.5) 8 (24.2) .446
Ischemic symptoms 18 (24.7) 2 (6.1) .023*
Stroke 1 (1.4) 0 (0.0) .496
Atrial fibrillation 6 (8.2) 0 (0.0) .090
Congestive heart failure 9 (12.3) 0 (0.0) .035*
Hospitalisation 44 (60.3) 13 (39.4) .046*
CV-hospitalisation 34 (46.6) 9 (28.1) .077
SUM 49 (66.2) 14 (42.4) .021*
* Chi-square p< 0.05
Comparison of eMVO+ and eMVO- patients according to the occurrence of
the secondary endpoints (*p< 0.05). eMVO: early microvascular obstruction,
CV: cardiovascular, CAG: coronary angiography.Figure 4 Kaplan-Meier curves showing the differences in event-
free survival between patients without early MVO (eMVO-) and
patients with early MVO (MVO-). MVO: microvascular obstruction.
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might be a lower number of coronary collaterals in
patients with MVO [43]. A second explanation might
be found on the level of the microvasculature itself.
An impaired endothelium-mediated vasodilation or
microvascular spasms during the acute event [44,45],
might represent a microvasculature prone to dysfunc-
tion, resulting in a higher number of recurrent ischemic
symptoms [46,47] and finally MACE [20].
Early re-admission rates for any cause have been pro-
posed as a quality standard after myocardial infarction
and represent not only comorbidities but also cardiovas-
cular disease extent. In general STEMI populations
~10% readmission rates have been reported [48]. In our
study 3 patients were re-admitted within 30 days
(2.8%). All of the admissons were of acute cardiovascular
nature and occurred in patients with eMVO. The higher
number of long-term admission rates in eMVO+patients
might represent a higher general and cardiovascularTable 2 Multivariate Cox regression analysis
Primary Endpoint (n = 63) p-value
HR 95%-CI
eMVO+ 2.20 (1.11 - 4.36) 0.02
Age> 57 years 0.96 (0.57 - 1.62) 0.87
EF< 40.6% 1.16 (0.67 - 1.99) 0.60
Infarct size> 19.77 g 0.69 (0.39 - 1.21) 0.20
Multivariate Cox regression analysis for the occurrence of the primary
endpoint. eMVO+: presence of early microvascular obstruction, EF: ejection
fraction, HR: hazard ratio, CI: confidence interval.morbidity of eMVO+patients, beside yet evaluated car-
diovascular factors[35].
In the OPTIMAAL trial it has been shown that atrial
fibrillation occurs in up to 6-7% of patients within 3 years
after first STEMI [49]. Further the presence of atrial fib-
rillation after STEMI is associated with worsening prog-
nosis [50]. To us it seems that atrial fibrillation after
STEMI is an important end-point, not only because of
prognostic reasons but also because of pathophysio-
logical considerations [51]. Factors associated with atrial
fibrillation after STEMI are age, male gender, history of
angina, higher Killip classes, higher diastolic blood pres-
sure, and higher pulse rate during the randomization
[49]. Some of these factors have also been shown to cor-
relate with infarct size or the presence of MVO [35].
We speculated that adverse remodeling [52] aggra-
vated by the presence of MVO is responsible for our
observations. In conclusion, we believe that in our study
population of relatively young (56.8 years) patients, the
presence of early MVO leads to a higher cardiovascular
morbidity after STEMI during a long term follow-up.
Conclusion
Early MVO, as assessed by first-pass CMR is an inde-
pendent long-term prognosticator for cardiovascular
morbidity after STEMI treated with pPCI. It is asso-
ciated with a higher prevalence of hypertension and
larger infarct size. Our results underline the need for
future pre- and post-interventional therapies to avoid
early MVO in acute STEMI.
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